GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (NAS:EVGN) » Definitions » Cyclically Adjusted PS Ratio

Evogene (Evogene) Cyclically Adjusted PS Ratio : 2.83 (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Evogene Cyclically Adjusted PS Ratio?

As of today (2024-04-29), Evogene's current share price is $0.65. Evogene's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.23. Evogene's Cyclically Adjusted PS Ratio for today is 2.83.

The historical rank and industry rank for Evogene's Cyclically Adjusted PS Ratio or its related term are showing as below:

EVGN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.67   Med: 2.45   Max: 4.54
Current: 3.09

During the past years, Evogene's highest Cyclically Adjusted PS Ratio was 4.54. The lowest was 1.67. And the median was 2.45.

EVGN's Cyclically Adjusted PS Ratio is ranked better than
62.45% of 506 companies
in the Biotechnology industry
Industry Median: 5.395 vs EVGN: 3.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Evogene's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.011. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.23 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Evogene Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Evogene's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evogene Cyclically Adjusted PS Ratio Chart

Evogene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3.68 1.87 3.63

Evogene Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.87 1.97 4.09 2.52 3.63

Competitive Comparison of Evogene's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Evogene's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evogene's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evogene's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evogene's Cyclically Adjusted PS Ratio falls into.



Evogene Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Evogene's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.65/0.23
=2.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evogene's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Evogene's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.011/129.4194*129.4194
=0.011

Current CPI (Dec. 2023) = 129.4194.

Evogene Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.155 99.695 0.201
201406 0.157 100.560 0.202
201409 0.129 100.428 0.166
201412 0.141 99.070 0.184
201503 0.103 99.621 0.134
201506 0.107 100.684 0.138
201509 0.127 100.392 0.164
201512 0.099 99.792 0.128
201603 0.078 100.470 0.100
201606 0.073 101.688 0.093
201609 0.060 101.861 0.076
201612 0.046 101.863 0.058
201703 0.028 102.862 0.035
201706 0.046 103.349 0.058
201709 0.029 104.136 0.036
201712 0.029 104.011 0.036
201803 0.014 105.290 0.017
201806 0.015 106.317 0.018
201809 0.014 106.507 0.017
201812 0.025 105.998 0.031
201903 0.014 107.251 0.017
201906 0.007 108.070 0.008
201909 0.004 108.329 0.005
201912 0.005 108.420 0.006
202003 0.003 108.902 0.004
202006 0.012 108.767 0.014
202009 0.012 109.815 0.014
202012 0.010 109.897 0.012
202103 0.009 111.754 0.010
202106 0.003 114.631 0.003
202109 0.004 115.734 0.004
202112 0.008 117.630 0.009
202203 0.006 121.301 0.006
202206 0.008 125.017 0.008
202209 0.011 125.227 0.011
202212 0.016 125.222 0.017
202303 0.015 127.348 0.015
202306 0.016 128.729 0.016
202309 0.077 129.860 0.077
202312 0.011 129.419 0.011

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evogene  (NAS:EVGN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Evogene Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Evogene's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evogene (Evogene) Business Description

Industry
Traded in Other Exchanges
Address
13 Gad Feinstein Street, Park Rehovot, P.O. Box 4173, Ness Ziona, Rehovot, ISR, 7414002
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.